Key trials of PARP inhibitors in advanced/MBC
| Clinical trial | Patient population | Phase | Treatment arms | Key endpoints: |
|---|---|---|---|---|
| OlympiAD [67] | gBRCA | III | Olaparib vs. PCT | PFS 7 months (olaparib) vs. 4.2 months (placebo) |
| MEDIOLA [68] | gBRCA | I/II | Olaparib followed by durvalumab | PFS 8.2 months; ORR 63%; OS 20.5 months |
| EMBRACA [19] | gBRCA | III | Talazoparib vs. PCT | PFS 8.8 months (talazoparib) vs. 5.6 months (placebo) |
| JAVELIN [69] | TNBC or gBRCA | I/II | Talazoparib + avelumab | ORR 24.4% (gBRCA1/2) and 4.9% (ATM) |
| BROCADE 3 [70] | gBRCA | III | Carboplatin + paclitaxel + veliparib vs. carboplatin + paclitaxel | PFS 14.5 months (carboplatin + paclitaxel + veliparib) vs. 12.6 months (carboplatin + paclitaxel); OS 33.5 months (carboplatin + paclitaxel + veliparib) vs. 28.2 months (carboplatin + paclitaxel) |
| TOPACIO/Keynote-162 [71] | TNBC | II | Nirabarib + pembrolizumab | PFS (BRCA-mutated group) 8.1 months |
gBRCA: germline mutations in the BReast CAncer (BRCA) gene; ORR: objective response rate; OS: overall survival; PFS: progression-free survival; PCT: physician’s choice of chemotherapy; TNBC: triple-negative breast cancer; ATM: ataxia telangiectasia-mutated